Total Payments
$7,447
2021 Payments
$374.95
Companies
17
Transactions
123
Medicare Patients
2,254
Medicare Billing
$156,640
Payment Breakdown by Category
Other$5,237 (70.3%)
Food & Beverage$1,719 (23.1%)
Education$490.93 (6.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Current or prospective ownership or investment interest | $5,237 | 2 | 70.3% |
| Food and Beverage | $1,719 | 110 | 23.1% |
| Education | $490.93 | 6 | 6.6% |
| Unspecified | $0 | 5 | 0.0% |
Payments by Type
General
$7,447
118 transactions
Ownership
$0
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Innovative Medical Technologies, LLC | $5,237 | 7 | $0 (2021) |
| Astellas Pharma US Inc | $1,008 | 40 | $0 (2021) |
| Janssen Biotech, Inc. | $408.16 | 26 | $0 (2021) |
| AbbVie Inc. | $190.44 | 12 | $0 (2021) |
| PFIZER INC. | $172.79 | 12 | $0 (2020) |
| MEDIVATION FIELD SOLUTIONS LLC | $116.01 | 6 | $0 (2018) |
| Avadel Specialty Pharmaceuticals, LLC | $104.41 | 7 | $0 (2018) |
| TOLMAR Pharmaceuticals, Inc. | $49.89 | 2 | $0 (2021) |
| MEDIVATION INC. | $46.23 | 2 | $0 (2017) |
| Ferring Pharmaceuticals Inc. | $22.73 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $374.95 | 23 | Janssen Biotech, Inc. ($221.57) |
| 2020 | $536.84 | 26 | Astellas Pharma US Inc ($265.58) |
| 2019 | $208.26 | 16 | Janssen Biotech, Inc. ($61.16) |
| 2018 | $548.91 | 34 | Astellas Pharma US Inc ($243.62) |
| 2017 | $5,778 | 24 | Innovative Medical Technologies, LLC ($5,237) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/30/2021 | AbbVie Inc. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/25/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $1.05 | General |
| Category: Oncology | ||||||
| 10/22/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $9.44 | General |
| Category: Oncology | ||||||
| 10/19/2021 | UROVANT SCIENCES INC | GEMTESA (Drug) | Food and Beverage | Cash or cash equivalent | $11.58 | General |
| Category: Urology | ||||||
| 10/12/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $1.58 | General |
| Category: Oncology | ||||||
| 10/11/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $10.94 | General |
| Category: Oncology | ||||||
| 10/04/2021 | Bayer HealthCare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: Oncology | ||||||
| 09/27/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: Oncology | ||||||
| 09/21/2021 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: ONCOLOGY | ||||||
| 08/08/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: Oncology | ||||||
| 07/06/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $5.21 | General |
| Category: Oncology | ||||||
| 07/02/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $8.80 | General |
| Category: Oncology | ||||||
| 06/07/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Education | In-kind items and services | $85.00 | General |
| Category: Oncology | ||||||
| 06/02/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $1.29 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $8.75 | General |
| Category: Oncology | ||||||
| 05/18/2021 | TOLMAR Pharmaceuticals, Inc. | ELIGARD (Drug) | Food and Beverage | In-kind items and services | $27.21 | General |
| Category: Prostate Cancer | ||||||
| 05/11/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: Oncology | ||||||
| 04/21/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: Oncology | ||||||
| 04/07/2021 | AbbVie Inc. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: ENDOCRINOLOGY | ||||||
| 03/23/2021 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $25.49 | General |
| Category: UROLOGY | ||||||
| 03/09/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Oncology | ||||||
| 02/02/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $14.35 | General |
| Category: Oncology | ||||||
| 2021 | Innovative Medical Technologies, LLC | — | — | — | $0.00 | Ownership |
| 12/22/2020 | TOLMAR Pharmaceuticals, Inc. | ELIGARD (Drug) | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: Prostate Cancer | ||||||
| 12/14/2020 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: UROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 14 | 1,104 | 1,387 | $197,229 | $75,984 |
| 2020 | 12 | 1,150 | 1,493 | $219,438 | $80,656 |
Total Patients
2,254
Total Services
2,880
Medicare Billing
$156,640
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 158 | 164 | $31,135 | $15,327 | 49.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 12 | 102 | $66,837 | $14,923 | 22.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 193 | 205 | $27,253 | $12,812 | 47.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 129 | 189 | $15,378 | $7,850 | 51.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 52 | 55 | $11,880 | $5,850 | 49.2% |
| 76872 | Ultrasound of pelvic region through rectum | Office | 2021 | 35 | 46 | $9,844 | $4,663 | 47.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 42 | 43 | $7,138 | $3,397 | 47.6% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2021 | 20 | 21 | $7,350 | $3,214 | 43.7% |
| 55700 | Biopsy of prostate gland | Office | 2021 | 11 | 11 | $4,136 | $2,162 | 52.3% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 42 | 42 | $4,830 | $2,000 | 41.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 27 | 41 | $2,665 | $1,232 | 46.2% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2021 | 16 | 42 | $2,730 | $1,033 | 37.8% |
| 81003 | Automated urinalysis test | Office | 2021 | 354 | 413 | $2,478 | $929.25 | 37.5% |
| 76942 | Ultrasonic guidance imaging supervision and interpretation for insertion of needle | Office | 2021 | 13 | 13 | $3,575 | $589.81 | 16.5% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2020 | 19 | 178 | $109,389 | $31,298 | 28.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 297 | 308 | $34,496 | $15,586 | 45.2% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 81 | 85 | $14,110 | $6,958 | 49.3% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2020 | 35 | 42 | $14,700 | $6,512 | 44.3% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 127 | 194 | $12,998 | $6,476 | 49.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 76 | 76 | $12,540 | $5,378 | 42.9% |
| 76872 | Ultrasound of rectum | Office | 2020 | 27 | 32 | $6,848 | $3,405 | 49.7% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2020 | 23 | 56 | $3,640 | $1,374 | 37.8% |
| 99201 | New patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 42 | 42 | $2,814 | $1,337 | 47.5% |
| 81003 | Automated urinalysis test | Office | 2020 | 397 | 453 | $2,718 | $1,013 | 37.3% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 14 | 14 | $1,610 | $730.93 | 45.4% |
About Dr. Gerald Ravitz, M.D
Dr. Gerald Ravitz, M.D is a Urology healthcare provider based in Pottsville, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174591515.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gerald Ravitz, M.D has received a total of $7,447 in payments from pharmaceutical and medical device companies, with $374.95 received in 2021. These payments were reported across 123 transactions from 17 companies. The most common payment nature is "Current or prospective ownership or investment interest" ($5,237).
As a Medicare-enrolled provider, Ravitz has provided services to 2,254 Medicare beneficiaries, totaling 2,880 services with total Medicare billing of $156,640. Data is available for 2 years (2020–2021), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Pottsville, PA
- Active Since 03/10/2006
- Last Updated 01/25/2011
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1174591515
Products in Payments
- XTANDI (Drug) $429.27
- ERLEADA (Drug) $335.20
- MYRBETRIQ (Drug) $308.20
- Xtandi (Drug) $159.92
- Noctiva (Drug) $104.41
- LUPRON DEPOT (Drug) $101.02
- Erleada (Drug) $72.96
- ELIGARD (Drug) $49.89
- TOVIAZ (Drug) $39.53
- Androgel (Drug) $38.26
- Myrbetriq (Drug) $32.98
- Lupron Depot (Drug) $29.37
- VIAGRA (Drug) $27.83
- FIRMAGON (Drug) $22.73
- Lupron (Drug) $21.79
- Nubeqa (Drug) $17.75
- PROVENGE (Drug) $13.17
- FOUNDATIONONE CDX (Device) $13.15
- KEYTRUDA (Biological) $12.87
- FLOSEAL (Biological) $11.75
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.